Rupatadine combined with ebastine for treatment of chronic urticaria: efficacy and impact on complement level and T lymphocytes
Objective:To evaluate the efficacy of rupatadine combined with ebastine in the treatment of chronic urticaria and explore their effect on complement levels and T lymphocytes.Methods:One hundred and eighty patients with chronic urticaria admitted from January 2020 to May 2021 were prospectively selected. They were divided into either a control group or an observation group using the random number table method. The control group (n=89) was treated with ebastine alone, and the observation group (n=91) was treated with rupatadine combined with ebastine. The therapeutic effects were compared between the two groups.Results:Pruritus (0.61±0.07) score, the number of wheals (0.56±0.08), erythema score (0.81±0.09), and total clinical symptom score (1.12±0.19) after 8 weeks of treatment, as well as the urticaria activity score after 4 (2.12±0.11) and 8 (0.76±0.12) weeks of treatment were significantly lower in the observation group than in the control group (P＜0.05). After 8 weeks of treatment, CD4+/CD8+ ratio (1.85±0.24), C3 [(0.65±0.15) g/L-1], C4 [(0.37±0.05) g/L-1], IFN-γ [(15.36±2.84) ng/ml], sVCAM-1 [(0.62±0.10) ng/L], LT [(53.34±5.22) pg/ml], IL-17 [(2.22±0.45) ng/L], and IL-4 [(15.86±2.36) pg/ml] were better in the observation group than in the control group (P＜0.05). In the observation group, the disease recovery rate after 4 weeks (58.24%), 6 weeks (73.63%), and 8 weeks (90.11%) of treatment were all significantly higher than those of the control group (P＜0.05).Conclusion:Rupatadine combined with ebastine in patients with chronic urticaria can improve the levels of T lymphocytes and complements, and relieve symptoms such as itching, wheals, and erythema.
万方数据
